全文获取类型
收费全文 | 3294269篇 |
免费 | 255284篇 |
国内免费 | 5967篇 |
专业分类
耳鼻咽喉 | 47392篇 |
儿科学 | 105271篇 |
妇产科学 | 88213篇 |
基础医学 | 466638篇 |
口腔科学 | 93569篇 |
临床医学 | 298969篇 |
内科学 | 643404篇 |
皮肤病学 | 69344篇 |
神经病学 | 273464篇 |
特种医学 | 129414篇 |
外国民族医学 | 1334篇 |
外科学 | 493629篇 |
综合类 | 74735篇 |
现状与发展 | 2篇 |
一般理论 | 1279篇 |
预防医学 | 265786篇 |
眼科学 | 76290篇 |
药学 | 246182篇 |
6篇 | |
中国医学 | 6403篇 |
肿瘤学 | 174196篇 |
出版年
2018年 | 37388篇 |
2017年 | 28180篇 |
2016年 | 30740篇 |
2015年 | 34698篇 |
2014年 | 48157篇 |
2013年 | 73642篇 |
2012年 | 102833篇 |
2011年 | 108231篇 |
2010年 | 62660篇 |
2009年 | 58835篇 |
2008年 | 101618篇 |
2007年 | 108462篇 |
2006年 | 108223篇 |
2005年 | 105319篇 |
2004年 | 101621篇 |
2003年 | 97921篇 |
2002年 | 95770篇 |
2001年 | 147733篇 |
2000年 | 152923篇 |
1999年 | 129709篇 |
1998年 | 37503篇 |
1997年 | 33970篇 |
1996年 | 33794篇 |
1995年 | 32587篇 |
1994年 | 30538篇 |
1993年 | 28503篇 |
1992年 | 104091篇 |
1991年 | 101146篇 |
1990年 | 97681篇 |
1989年 | 94017篇 |
1988年 | 87114篇 |
1987年 | 85805篇 |
1986年 | 80974篇 |
1985年 | 77469篇 |
1984年 | 58768篇 |
1983年 | 50029篇 |
1982年 | 30138篇 |
1981年 | 27008篇 |
1979年 | 54733篇 |
1978年 | 38330篇 |
1977年 | 32479篇 |
1976年 | 30468篇 |
1975年 | 32454篇 |
1974年 | 39555篇 |
1973年 | 37731篇 |
1972年 | 35176篇 |
1971年 | 32358篇 |
1970年 | 30644篇 |
1969年 | 28405篇 |
1968年 | 25886篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
Javed Butler Mei Yang Massimiliano Alfonzo Manzi Gregory P. Hess Mahesh J. Patel Thomas Rhodes Michael M. Givertz 《Journal of the American College of Cardiology》2019,73(8):935-944
Background
Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.Objectives
The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.Methods
Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.Results
Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.Conclusions
In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy. 相似文献22.
23.
Optimizing glycemic control remains a shared challenge for clinicians and their patients with diabetes. Flash continuous glucose monitoring (CGM) provides immediate information about an individual’s current and projected glucose level, allowing users to respond promptly to mitigate or prevent pending hypoglycemia or hyperglycemia. Large randomized controlled trials (RCTs) have demonstrated the glycemic benefits of flash CGM use in both type 1 and type 2 diabetes. However, whereas RCTs are mostly focused on the efficacy of this technology in defined circumstances, real-world studies can assess its effectiveness in wider clinical settings. This review assesses the most recent real-world studies demonstrating the effectiveness of flash CGM use to improve clinical outcomes and health care resource utilization in populations with diabetes.During the past 5 years, increasing numbers of people with type 1 or type 2 diabetes have integrated continuous glucose monitoring (CGM) into their diabetes self-management regimens. Unlike traditional blood glucose meters, CGM systems provide immediate information about the concentration and the direction and rate of change of interstitial glucose. This information enables patients to intervene promptly to prevent or reduce acute hypoglycemia or hyperglycemia.Flash CGM is among the most recent CGM technologies. Currently, the FreeStyle Libre 14-day system (Abbott Diabetes Care) and FreeStyle Libre 2 are the only flash CGM systems available, and these systems are being adopted rapidly. Large randomized controlled trials (RCTs) have confirmed the glycemic benefits of flash CGM use in people with type 1 diabetes (1,2) and those with type 2 diabetes (3–6). However, because RCTs are mostly focused on measures of efficacy in defined circumstances, real-world studies can usefully assess the effectiveness of flash CGM in wider clinical settings.Although adoption of flash CGM continues to expand within endocrinology and diabetes specialty practices, primary care providers may be less familiar with this technology and how it can benefit patients with diabetes. This review assesses recent real-world studies demonstrating the impact of flash CGM use on clinical outcomes and health care resource utilization in both type 1 and type 2 diabetes populations. 相似文献
24.
25.
26.
Thiago E. Sabino Vivian I. Avelino-Silva Clara Cavalcantte Silvia P. Goulart Olinda C. Luiz Luiz A.M. Fonseca 《AIDS care》2021,33(1):31-38
ABSTRACT This study focused on factors associated with antiretroviral therapy (ART) adherence and quality of life among transgenderwomen in Sao Paulo, Brazil, using univariable and adjusted analysis. Adherence was evaluated with a self-report tool and with HIV viral load (VL) measurement. PROQOL-HIV was used to assess quality of life. 106 TGW with median 41 years old were included; most were white (56%) and had >10 years of education (57%). Median time since HIV/AIDS diagnosis was 10 years. Overall, participants had high T CD4+ counts (median 659 cells/mm3) and most (75%) had undetectable HIV VL. 85% were considered adherent using self-report (95%CI 77-91), whereas 72% (95%CI 62-80) were considered adherent when self-report and undetectable HIV VL were analyzed jointly. Older age was associated with higher ART adherence; each year increase in age was associated with 5% higher odds of adherence (p?=?0.021). Quality of life ranged from good-excellent in 5 of 8 domains. Younger age, lower education, higher time since HIV diagnosis, comorbidities, illicit drugs use and depression were associated with lower PROQOL scores in specific domains in univariable analysis, while depression was also associated with lower total PROQOL score even after adjustment for age, comorbidities and time since HIV diagnosis (p?=?0.048). 相似文献
27.
28.
T. Maishman H. Sheikh P. Boger J. Kelly K. Cozens A. Bateman S. Davies M. Fay D. Sharland A. Jackson 《Clinical oncology (Royal College of Radiologists (Great Britain))》2021,33(5):e225-e231
AimsSelf-expanding metal stents provide rapid improvement of dysphagia in oesophageal cancer but are associated with complications. The aim of the present study was to test the effectiveness of an alternative treatment of combining biodegradable stents with radiotherapy.Materials and methodsA Simon two-stage single-arm prospective phase II trial design was used to determine the efficacy of biodegradable stents plus radiotherapy in patients with dysphagia caused by oesophagus cancer who were unsuitable for radical treatment. Fourteen patients were recruited and data from 12 were included in the final analyses.ResultsFive of 12 patients met the primary end point: one stent-related patient death; four further interventions for dysphagia within 16 weeks of stenting (41.7%, 95% confidence interval 15.2–72.3%). The median time to a 10-point deterioration of quality of life was 2.7 weeks. Nine patients died within 52 weeks of registration. The median time to death from any cause was 15.0 weeks (95% confidence interval 9.6–not reached).ConclusionThe high re-intervention observed, which met the pre-defined early stopping criteria, meant that the suggested alternative treatment was not sufficiently effective to be considered for a larger scale trial design. Further work is needed to define the place of biodegradable stents in the management of malignant oesophageal strictures. 相似文献
29.
Neal A. Carnes James W. Carey Deborah J. Gelaude Damian J. Denson Patricia A. Bessler 《AIDS care》2021,33(1):63-69
ABSTRACT Expeditious linkage and consistent engagement in medical care is important for people with HIV’s (PWH) health. One theory on fostering linkage and engagement involves HIV status disclosure to mobilize social support. To assess disclosure and social support’s association with linkage and engagement, we conducted a qualitative study sampling black and Latino men who have sex with men (MSM of color) in the U.S. Participants' narratives presented mixed results. For instance, several participants who reported delaying, inconsistent access, or detachment from care also reported disclosing for support purposes, yet sporadic engagement suggests that their disclosure or any subsequent social support have not assisted. The findings contribute to the literature that questions disclosure and social support’s influence on care engagement, especially when decontextualized from circumstances and intentions. Our findings suggest the mechanics of disclosure and social support require planned implementation if intending to affect outcomes, especially among MSM of color. From the findings, we explore steps that may bolster interventions seeking to anchor medical care engagement. 相似文献
30.
Claire Périllaud Benoît Pilmis Julien Diep Gauthier Péan de Ponfilly Barbara Vidal Carine Couzigou Assaf Mizrahi Julie Lourtet-Hascoët Alban Le Monnier Jean-Claude Nguyen Van 《Diagnostic microbiology and infectious disease》2019,93(1):14-21